Inhibition of Che-1/AATF as a New Tool in Multiple Myeloma Treatment

Multiple Myeloma Clinical Trial

— AATF/Che-1  

Official title:

Inhibition of Che-1/AATF as a New Tool in Multiple Myeloma Treatment

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05858203
• Other study ID #: RS1442/20
• Status: Recruiting
• Start date: December 22, 2020
• Est. completion date: December 31, 2025

Study information

• Verified date: March 2023
• Source: Regina Elena Cancer Institute
• Contact: Maurizio fanciulli, PhD
• Phone: +39 06 52662800
• Email: maurizio.fanciulli[@]ifo.it
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Multiple myeloma (MM) is a haematological malignancy characterized by the accumulation of proliferating antibody producing plasma cells in the bone marrow. In the last few years many studies have emphasized the biological complexity and heterogeneity of MM as a result of both genetic and epigenetic aberrations. Che-1/AATF (Che-1) is a transcriptional cofactor involved in cell cycle regulation, apoptosis, DNA damage and stress response. it can be hypothesized that Che-1 might contribute to the establishment of the MM malignant phenotype by sustaining global transcription through its ability to modulate chromatin accessibility.

The prospective study on MM human samples aims to understand the involvement of Che-1 in the transcriptional regulation and chromatin remodeling during the pathology. To this goal the main objectives are:

• Characterization of Che-1's role in chromatin remodeling and global gene expression

• Study in vivo and in vitro of Che-1 involvement in MM tumorigenesis

• Evaluation of Che-1 as a possible therapeutic target

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: December 31, 2025
• Est. primary completion date: March 21, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• MM Patients

Exclusion Criteria:

• No exclusion criteria

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Other:
• ATAC-seq and ChIP-seq
CD138+ cells will be isolated from the bone marrow of MM patients and will be subjected to ATAC-seq and ChIP-seq analyses, by useing specific antibodies, to better understand the involvment of Che-1 in MM tumorogenesis.

Locations

Country	Name	City	State
Italy	Regina elena Cancer Institute	Roma
Italy	"Regina Elena" National Cancer Institute	Rome

Sponsors (1)

Lead Sponsor	Collaborator
Regina Elena Cancer Institute

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Che-1 involvement in MM tumorigenesis	Characterization of Che-1's role in chromatin remodeling and global gene expression	About 2 years